0002-4736 : Reyvow 200 mg Oral Tablet
| NDC: | 0002-4736 |
| Labeler: | Eli Lilly and Company |
| Product Type: | Human Prescription Drug |
| Drug Name: |  Reyvow |
| Dosage Form: | Oral Tablet |
| Application #: | NDA211280 |
| Rev. Date: | |
| CSA Schedule: | CV (US) [1] |
[1] Schedule V Controlled Substance: Low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. (i.e. Cough preparations containing not more than 200 milligrams of Codeine per 100 milliliters or per 100 grams [such as Robitussin AC, Phenergan with Codeine], and Ezogabine). More Details: US Dept of Justice Controlled Substance Schedules.
NDC Package Codes:
- 0002-4736-08: 2 BLISTER PACK IN 1 CARTON (0002‑4736‑08) > 4 TABLET IN 1 BLISTER PACK
Active Ingredients:
- Lasmiditan
Dosage Strength:
- 200 mg
Related Products:
Based on records with the same trade name.- 0002-4312 Reyvow 50 mg Oral Tablet by Eli Lilly and Company
- 0002-4491 Reyvow 100 mg Oral Tablet by Eli Lilly and Company
NDC QR Code
Scan the QR code below to easily reference this data in the future:
< Prev: 0002-4732Next: 0002-4770 >
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.